March 6, 2015—Genentech's decision last fall to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the specialty distribution channel has cost hospitals more than $300 million and disrupted patient care, a survey of more than 200 hospitals has found. Nearly two out of five hospitals (39 percent) surveyed said the change affects their risk of 340B program … [Read more...]
MedPAC: No 340B Recommendations to Congress This Year
June report will include a chapter about 340B, but it won't suggest any changesMarch 6, 2015—The Medicare Payment Advisory Commission will include a chapter about the 340B program in its June report to Congress, Chairman Glenn Hackbarth said during yesterday's commission meeting. But it will make no recommendations about 340B at this time, he added, and it remains up in the air whether the commission will make such recommendations at all. … [Read more...]
HRSA Has Sharpened 340B Oversight, Agencies Tell House Panel
Written testimony posted in advance of hearing, which has been postponedMarch 4, 2015—The Health Resources and Services Administration has significantly strengthened its oversight of the 340B program in recent years, government witnesses say in written testimony submitted in advance of a congressional hearing on the drug discount program. … [Read more...]
Hospital Outpatient Departments Treat Sicker, Poorer Patients, Study Finds
Research released amid debate over site-neutral paymentsMarch 4, 2015—Patients receiving care in hospital outpatient departments are sicker and poorer than those receiving care in physician offices and could lose access to care if Congress significantly reduces payments to outpatient departments, a new study has found. … [Read more...]
House Appropriations Chairman Questions 340B User Fee
Levy will "wreak havoc" in rural areas, Rep. Rogers saysMarch 4, 2015—The Obama administration's proposed 0.1 percent user fee on 340B drug purchases "will wreak havoc on healthcare providers, especially those in rural areas," the chairman of the House Appropriations Committee has told the Secretary of Health and Human Services. … [Read more...]
PhRMA Says HRSA Misinterprets 340B Orphan Drug Exclusion
Asks court to declare interpretive rule invalidFebruary 26, 2015—The Department of Health and Human Services Health Resources and Services Administration cannot second-guess Congress and rewrite the 340B orphan drug exclusion "to make the statute correspond with the agency's policy preference," brand-name drugmakers said yesterday in a court filing. … [Read more...]
House Subcommittee Holding 340B Hearing Next Week
Will hear from government witnesses on March 5February 25, 2015—The House Energy & Commerce Health Subcommittee has scheduled a hearing on the 340B program for March 5 at 10:00 a.m. … [Read more...]